(Marketwired) – 11/06/14 – Medivation, Inc. (NASDAQ:MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI® (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million… Read more »
Shares of Medivation closed yesterday at $107.94 . MDVN has a 1-year high of $117.23 and a 1-year low of $54.37. The stock’s 50-day moving average is $104.48 and it’s 200-day moving average is $96.99.
On the ratings front, Medivation has been the subject of a number of recent research reports. In a report released yesterday, Stifel Nicolaus analyst Joel Sendek reiterated a Buy rating on MDVN, with a price target of $128, which reflects a potential upside of 18.6% from last closing price. Separately, on January 22, Brean Murray Carret’s Jonathan Aschoff maintained a Buy rating on the stock and has a price target of $118.
In total, 9 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $107.94 which is 14.0% above where the stock closed yesterday.
Medivation, Inc. is a biopharmaceutical company engaged in the development of novel small molecule drugs to treat diseases like Alzheimer’s disease and Huntington disease.